Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevira in high-grade squamous intraepithelial lesions of the cervix (HSIL) – Phase 3
2020-001342-19Phase 3Completed
- Sponsor
- Asieris Pharmaceuticals
- Start
- Sep 2020
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cervical intraepithelial neoplasia (CIN) comparing Cevira with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Sep 2020; status: completed.
02
Drugs
Cevira
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2020-001342-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001342-19.